Author: DrugPatentWatch - Page 32 - DrugPatentWatch

Drug Spending in the US: Where the Money Actually Goes

Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.

Businessman and investor Mark Cuban is probably best known as the owner of the Dallas Mavericks and as an investor

Anticipate the Future Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what’s next. We understand

The average time to market for a new drug is around 12 years, at a cost averaging $2.6 billion, according

By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity

In November 2018, the Government Accountability Office (GAO) released a report titled “FDA Could Improve Designation Review Consistency; Rare Disease

Meet DrugPatentWatch at the following trade shows and conferences we will be attending in 2019: Access! 2019 AAM Annual Meeting: February

This article was originally published by Nigel S. Clarke in World Patent Information Volume 54, Supplement, September 2018, Pages S4-S10 under

This article was originally published by Hao Zhong, Ging Chan, Yuanjia Hu, Hao Hu and Defang Ouyang in Pharmaceutics 2018, 10(4), 263